(Q52927347)

9 May 2018

editorial

0 references

review article

1 reference

title

Health economists meet the fourth tempter: drug dependency and scientific discourse. (English)

1 reference

9 May 2018

author name string

Morgan S

series ordinal

1

1 reference

9 May 2018

Barer M

series ordinal

2

1 reference

9 May 2018

Evans R

series ordinal

3

1 reference

9 May 2018

language of work or name

English

0 references

publication date

1 December 2000

1 reference

9 May 2018

published in

Health Economics

1 reference

9 May 2018

volume

9

1 reference

9 May 2018

issue

8

1 reference

9 May 2018

page(s)

659-667

1 reference

9 May 2018

Avoiding bias in the conduct and reporting of cost-effectiveness research sponsored by pharmaceutical companies.

cites work

1 reference

https://api.crossref.org/works/10.1002%2F1099-1050%28200012%299%3A8%3C659%3A%3AAID-HEC578%3E3.0.CO%3B2-0

Something rotten in the state of clinical and economic evaluations?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1050%28200012%299%3A8%3C659%3A%3AAID-HEC578%3E3.0.CO%3B2-0

Why is the pharmaceutical industry investing increasing amounts in health economic evaluations?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1050%28200012%299%3A8%3C659%3A%3AAID-HEC578%3E3.0.CO%3B2-0

Making economic evaluations respectable

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1050%28200012%299%3A8%3C659%3A%3AAID-HEC578%3E3.0.CO%3B2-0

A reappraisal of economic evaluation of pharmaceuticals. Science or marketing?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1050%28200012%299%3A8%3C659%3A%3AAID-HEC578%3E3.0.CO%3B2-0

Paying the piper for pharmacoeconomic studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1050%28200012%299%3A8%3C659%3A%3AAID-HEC578%3E3.0.CO%3B2-0

Conflict of interest and cost-effectiveness analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1050%28200012%299%3A8%3C659%3A%3AAID-HEC578%3E3.0.CO%3B2-0

BMJ should declare its own conflict of interest

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1050%28200012%299%3A8%3C659%3A%3AAID-HEC578%3E3.0.CO%3B2-0

Acceptance of external funds by physician organizations: issues and policy options.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1050%28200012%299%3A8%3C659%3A%3AAID-HEC578%3E3.0.CO%3B2-0

Consensus conferences as drug promotion

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1050%28200012%299%3A8%3C659%3A%3AAID-HEC578%3E3.0.CO%3B2-0

When pharmaceutical manufacturers' employees present grand rounds, what do residents remember?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1050%28200012%299%3A8%3C659%3A%3AAID-HEC578%3E3.0.CO%3B2-0

Influences on the quality of published drug studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1050%28200012%299%3A8%3C659%3A%3AAID-HEC578%3E3.0.CO%3B2-0

Fair conduct and fair reporting of clinical trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1050%28200012%299%3A8%3C659%3A%3AAID-HEC578%3E3.0.CO%3B2-0

Problems in the design and reporting of trials of antifungal agents encountered during meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1050%28200012%299%3A8%3C659%3A%3AAID-HEC578%3E3.0.CO%3B2-0

Secrecy in medical research.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1050%28200012%299%3A8%3C659%3A%3AAID-HEC578%3E3.0.CO%3B2-0

Is Academic Medicine for Sale?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1050%28200012%299%3A8%3C659%3A%3AAID-HEC578%3E3.0.CO%3B2-0

The industrialization of clinical research.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1050%28200012%299%3A8%3C659%3A%3AAID-HEC578%3E3.0.CO%3B2-0

Uneasy alliance--clinical investigators and the pharmaceutical industry

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1050%28200012%299%3A8%3C659%3A%3AAID-HEC578%3E3.0.CO%3B2-0

The journal's policy on cost-effectiveness analyses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1050%28200012%299%3A8%3C659%3A%3AAID-HEC578%3E3.0.CO%3B2-0

The quality of reporting in published cost-utility analyses, 1976-1997.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1050%28200012%299%3A8%3C659%3A%3AAID-HEC578%3E3.0.CO%3B2-0

Evaluation of conflict of interest in economic analyses of new drugs used in oncology

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1050%28200012%299%3A8%3C659%3A%3AAID-HEC578%3E3.0.CO%3B2-0

Problems with the interpretation of pharmacoeconomic analyses: a review of submissions to the Australian Pharmaceutical Benefits Scheme

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1050%28200012%299%3A8%3C659%3A%3AAID-HEC578%3E3.0.CO%3B2-0

10.1002/1099-1050(200012)9:8<659::AID-HEC578>3.0.CO;2-0

21 January 2018

Identifiers

DOI

1 reference

9 May 2018

1 reference

9 May 2018